Form 4: NEOGENOMICS CFO Buys 20,000 Shares

Neogenomics Inc.'s Chief Financial Officer, Jeffrey Scott Sherman, reported the acquisition of 20,000 shares of common stock in a transaction dated August 6, 2025.

Summary

• Jeffrey Scott Sherman, Chief Financial Officer of Neogenomics Inc. (NEO), reported an acquisition of 20,000 shares of common stock.
• The transaction occurred on August 6, 2025, at a price of $5.6161 per share.
• Following this transaction, Mr. Sherman directly beneficially owns 188,332 shares of common stock.
• The filing also details various derivative securities held, including multiple tranches of stock options, restricted stock units (RSUs), and performance stock units (PSUs).
• Notable grants include 249,169 stock options (granted December 5, 2022, exercise price $11.62), 73,016 stock options (granted May 11, 2023, exercise price $19.65), and 214,900 premium-price stock options (granted February 21, 2025, exercise price $13.05).
• RSUs include 13,006 (granted May 11, 2023), 59,382 (vesting April 13, 2026), 31,071 (granted February 23, 2024), and 126,476 (granted February 21, 2025).
• PSUs include 39,016 (granted May 11, 2023, target, maximum 58,524) and 46,606 (granted February 23, 2024, target, maximum 69,910, based on share and revenue growth).

Sentiment

Score: 7

Explanation: The CFO's direct purchase of company stock is a strong signal of confidence in the company's future, outweighing the minor administrative discrepancies in the filing.

Positives

• Chief Financial Officer Jeffrey Scott Sherman acquired 20,000 shares of common stock, indicating management confidence in the company's future.
• The acquisition increases Mr. Sherman's direct beneficial ownership to 188,332 shares, aligning his interests further with shareholders.

Negatives

• The reported transaction date of August 6, 2025, is in the future, which is unusual for a Form 4 filing that typically reports completed transactions.
• There is a discrepancy between the number of restricted stock units (31,071) listed in the table and the number (46,606) mentioned in the corresponding explanation for the February 23, 2024 grant.

Future Outlook

The filing does not provide explicit forward-looking statements or guidance beyond the vesting schedules and performance criteria for equity awards, which imply continued service and achievement of company goals.

Industry Context

This insider purchase by the CFO of Neogenomics Inc. is a company-specific event and does not directly reflect broader industry trends. However, insider buying can signal management's positive outlook on the company's prospects within its sector.

Comparison to Industry Standards

• This filing is a Form 4 detailing an insider transaction and equity holdings, not a financial performance report. Therefore, it does not contain information suitable for comparison to industry-wide financial benchmarks or competitor results.

Related Party Transactions

• Jeffrey Scott Sherman, as Chief Financial Officer, acquired 20,000 shares of common stock from the issuer, which is a direct related party transaction.

Stakeholder Impact

• Shareholders: The CFO's purchase may instill confidence in the company's prospects, potentially leading to positive sentiment and increased investor interest.
• Employees: The equity grants to the CFO, tied to performance and continued service, align management incentives with company success, which can indirectly benefit employees through a stronger company.

Next Steps

• Continued vesting of various stock options, restricted stock units, and performance stock units according to their respective schedules.
• Achievement of share growth and revenue growth goals for performance stock units.

Key Dates

Recommendation

While the CFO's purchase of company stock is a positive signal of insider confidence, a single Form 4 filing typically does not provide enough comprehensive financial or strategic information to warrant a 'buy' or 'sell' recommendation. It suggests a positive internal view, but investors should consider this alongside broader financial performance, market conditions, and industry trends before making a definitive investment decision. Therefore, a 'hold' recommendation is appropriate, encouraging further analysis.

Keywords

NEOGENOMICS, NEO, Insider Trading, Form 4, Stock Purchase, CFO, Jeffrey Scott Sherman, Equity Acquisition, Restricted Stock Units, Performance Stock Units, Stock Options